2023-506871-88-00招募中1 期
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 196
- 试验地点
- 20
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Global Clinical Trials Helpdesk
Scientific
AbbVie Deutschland GmbH & Co. KG
研究点 (20)
Loading locations...
相似试验
招募中
不适用
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants with Moderate to Severe Atopic DermatitisAtopic DermatitisjRCT2011230002AbbVie G.K.880
已完成
不适用
Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With SchizophreniaSchizophreniajRCT2031220096AbbVie G.K.250
招募中
不适用
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants with Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400jRCT2031210395AbbVie G.K.50
招募中
不适用
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic MigrainejRCT2051230212AbbVie GK450
进行中（未招募）
不适用
A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult ParticipantsjRCT2031230467AbbVie GK250